Loading...
OTCM
BICX
Market cap8mUSD
Jul 09, Last price  
0.40USD
1D
0.00%
1Q
53.55%
Jan 2017
-86.67%
IPO
-75.00%
Name

BioCorRx Inc

Chart & Performance

D1W1MN
OTCM:BICX chart
P/E
P/S
10.48
EPS
Div Yield, %
Shrs. gr., 5y
28.01%
Rev. gr., 5y
45.41%
Revenues
797k
+10,301.10%
000771,762868,161714,9621,170,922924,732701,772657,271376,656240,259122,62148,272213,84189,1607,665797,244
Net income
-3m
L-32.63%
-5,021-13,197-23,086-408,967-885,807-3,838,522-3,127,780-4,665,990-5,903,982-29,705,669-6,511,891-7,708,270-4,014,989-5,803,167-4,369,413-3,766,913-5,106,124-3,440,146
CFO
-2m
L+109.65%
-1,046-7,750-15,510-129,290-927,758103,458167,66947,859-1,987,100-2,540,395-1,825,623-2,937,127-2,151,872-3,537,658-2,041,773-1,853,282-1,096,254-2,298,291

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

BioCorRx Inc. (BICX), through its various operations, is dedicated to creating and delivering therapeutic solutions for individuals struggling with substance dependence and related health conditions across the United States. Among its core offerings is the BioCorRx recovery program, an innovative, non-addictive treatment model. This program uniquely combines proprietary naltrexone implants with extensive counseling services to support patient recovery. Additionally, the company provides the UnCraveRx weight management program, a medically supported initiative designed to curb food cravings. This program integrates pharmacological assistance with readily available virtual support focusing on lifestyle adjustments, fitness, and nutritional guidance. Looking to the future, BioCorRx is actively advancing its product pipeline. This includes BICX101, an injectable naltrexone product, and BICX104, an implantable naltrexone device, both currently under development for the specific treatment of opioid addiction and alcoholism. The company's programs are made available to patients through a network of healthcare providers, independent licensed clinics, and other qualified healthcare professionals. Originally established as Fresh Start Private Management, Inc., the organization officially rebranded as BioCorRx Inc. in January 2014. Its corporate headquarters are situated in Anaheim, California.
IPO date
Aug 31, 2010
Employees
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT